Challenging Issues in Pediatric Oncology

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2011 Jun 29

PMID 21709698

Citations 102

Authors

Ching-Hon Pui

Amar J Gajjar

Javier R Kane

Ibrahim A Qaddoumi

Alberto S Pappo

Affiliations

Soon will be listed here.

Abstract

Improvements in protocol-driven clinical trials and supportive care for children and adolescents with cancer have reduced mortality rates by more than 50% over the past three decades. Overall, the 5-year survival rate for patients with pediatric cancer has increased to approximately 80%. Recognition of the biological heterogeneity within specific subtypes of cancer, the discovery of genetic lesions that drive malignant transformation and cancer progression, and improved understanding of the basis of drug resistance will undoubtedly catalyze further advances in risk-directed treatments and the development of targeted therapies, boosting the cure rates further. Emerging new treatments include novel formulations of existing chemotherapeutic agents, monoclonal antibodies against cancer-associated antigens, and molecular therapies that target genetic lesions and their associated signaling pathways. Recent findings that link pharmacogenomic variations with drug exposure, adverse effects, and efficacy should accelerate efforts to develop personalized therapy for individual patients. Finally, palliative care should be included as an essential part of cancer management to prevent and relieve the suffering and to improve the quality of life of patients and their families.

Citing Articles

Advances in the Repurposing and Blood-Brain Barrier Penetrance of Drugs in Pediatric Brain Tumors.

Rechberger J, Toll S, Biswas S, You H, Chow W, Kendall N Cancers (Basel). 2025; 17(3).

PMID: 39941807 PMC: 11816256. DOI: 10.3390/cancers17030439.

Perivascular space imaging during therapy for medulloblastoma.

Song R, Glass J, Wu S, Li Y, Robinson G, Gajjar A PLoS One. 2025; 20(2):e0318278.

PMID: 39919146 PMC: 11805390. DOI: 10.1371/journal.pone.0318278.

Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics.

Velz J, Freudenmann L, Medici G, Dubbelaar M, Mohme M, Ghasemi D Nat Commun. 2025; 16(1):1364.

PMID: 39904979 PMC: 11794601. DOI: 10.1038/s41467-025-56268-0.

Bridging molecular advancements and clinical challenges in pediatric oncology.

Kuhlen M, Fruhwald M World J Pediatr. 2024; 21(2):120-122.

PMID: 39695048 PMC: 11885346. DOI: 10.1007/s12519-024-00870-7.

Genomic Newborn Screening for Pediatric Cancer Predisposition Syndromes: A Holistic Approach.

Linga B, Mohammed S, Farrell T, Rifai H, Al-Dewik N, Qoronfleh M Cancers (Basel). 2024; 16(11).

PMID: 38893137 PMC: 11171256. DOI: 10.3390/cancers16112017.

References

Rudin C, Hann C, Laterra J, Yauch R, Callahan C, Fu L . Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009; 361(12):1173-8. PMC: 5317279. DOI: 10.1056/NEJMoa0902903. View

Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M . A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007; 370(9583):240-250. DOI: 10.1016/S0140-6736(07)61126-X. View

Baker J, Barfield R, Hinds P, Kane J . A process to facilitate decision making in pediatric stem cell transplantation: the individualized care planning and coordination model. Biol Blood Marrow Transplant. 2007; 13(3):245-54. DOI: 10.1016/j.bbmt.2006.11.013. View

Tekautz T, Fuller C, Blaney S, Fouladi M, Broniscer A, Merchant T . Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol. 2005; 23(7):1491-9. DOI: 10.1200/JCO.2005.05.187. View

Vickers J, Thompson A, Collins G, Childs M, Hain R . Place and provision of palliative care for children with progressive cancer: a study by the Paediatric Oncology Nurses' Forum/United Kingdom Children's Cancer Study Group Palliative Care Working Group. J Clin Oncol. 2007; 25(28):4472-6. DOI: 10.1200/JCO.2007.12.0493. View

Pfister S, Janzarik W, Remke M, Ernst A, Werft W, Becker N . BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008; 118(5):1739-49. PMC: 2289793. DOI: 10.1172/JCI33656. View

Agaram N, LaQuaglia M, Ustun B, Guo T, Wong G, Socci N . Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res. 2008; 14(10):3204-15. PMC: 3805121. DOI: 10.1158/1078-0432.CCR-07-1984. View

Jones D, Kocialkowski S, Liu L, Pearson D, Backlund L, Ichimura K . Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008; 68(21):8673-7. PMC: 2577184. DOI: 10.1158/0008-5472.CAN-08-2097. View

Baker D, Schmidt M, Cohn S, Maris J, London W, Buxton A . Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010; 363(14):1313-23. PMC: 2993160. DOI: 10.1056/NEJMoa1001527. View

10.

Veerman A, Kamps W, van den Berg H, van den Berg E, Bokkerink J, Bruin M . Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol. 2009; 10(10):957-66. DOI: 10.1016/S1470-2045(09)70228-1. View

11.

Mullighan C, Miller C, Radtke I, Phillips L, Dalton J, Ma J . BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008; 453(7191):110-4. DOI: 10.1038/nature06866. View

12.

Ferris F, Bruera E, Cherny N, Cummings C, Currow D, Dudgeon D . Palliative cancer care a decade later: accomplishments, the need, next steps -- from the American Society of Clinical Oncology. J Clin Oncol. 2009; 27(18):3052-8. DOI: 10.1200/JCO.2008.20.1558. View

13.

Cornely O, Maertens J, Winston D, Perfect J, Ullmann A, Walsh T . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356(4):348-59. DOI: 10.1056/NEJMoa061094. View

14.

Pui C, Howard S . Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008; 9(3):257-68. DOI: 10.1016/S1470-2045(08)70070-6. View

15.

Northcott P, Korshunov A, Witt H, Hielscher T, Eberhart C, Mack S . Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2010; 29(11):1408-14. PMC: 4874239. DOI: 10.1200/JCO.2009.27.4324. View

16.

Puget S, Grill J, Valent A, Bieche I, Dantas-Barbosa C, Kauffmann A . Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas. J Clin Oncol. 2009; 27(11):1884-92. DOI: 10.1200/JCO.2007.15.4195. View

17.

Forshew T, Tatevossian R, Lawson A, Ma J, Neale G, Ogunkolade B . Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol. 2009; 218(2):172-81. DOI: 10.1002/path.2558. View

18.

Carol H, Lock R, Houghton P, Morton C, Kolb E, Gorlick R . Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009; 53(7):1255-63. PMC: 2763980. DOI: 10.1002/pbc.22056. View

19.

Wachtel M, Schafer B . Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev. 2010; 36(4):318-27. DOI: 10.1016/j.ctrv.2010.02.007. View

20.

Pui C, Gaynon P, Boyett J, Chessells J, Baruchel A, Kamps W . Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002; 359(9321):1909-15. DOI: 10.1016/S0140-6736(02)08782-2. View